Phio Pharmaceuticals Announces Initiation Of Collaborative Clinical Trial With PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) And Providence Cancer Institute
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals has initiated a collaborative clinical trial with its PH-762 compound, AgonOx's tumor infiltrating lymphocyte program (AGX148), and Providence Cancer Institute. The trial aims to evaluate the safety and efficacy of the combined therapy in cancer patients.
May 24, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phio Pharmaceuticals initiates a clinical trial with PH-762, AgonOx's AGX148, and Providence Cancer Institute, potentially leading to positive outcomes for the company.
The initiation of the collaborative clinical trial with PH-762, AgonOx's AGX148, and Providence Cancer Institute is a significant development for Phio Pharmaceuticals. If the trial demonstrates positive results in terms of safety and efficacy, it could lead to increased investor confidence and a potential rise in the stock price of PHIO in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100